甲磺酸伊马替尼治疗晚期胃肠间质瘤的临床疗效观察 |
| |
引用本文: | 陈杰,钟克力,郭春华,夏利刚,潘凯. 甲磺酸伊马替尼治疗晚期胃肠间质瘤的临床疗效观察[J]. 河北医学, 2011, 17(3): 334-336. DOI: 10.3969/j.issn.1006-6233.2011.03.019 |
| |
作者姓名: | 陈杰 钟克力 郭春华 夏利刚 潘凯 |
| |
作者单位: | 广东省深圳市人民医院胃肠外科,广东,深圳,518020 |
| |
摘 要: | 目的:评价甲磺酸伊马替尼治疗晚期胃肠间质瘤的临床疗效和不良反应。方法:2006年10月至20010年10月期间经病理检查确诊的25例晚期胃肠间质瘤患者,使用甲磺酸伊马替尼400mg/日治疗。结果:25例病人均得到随访,完全缓解(CR)0例,部分缓解(PR)13例,疾病稳定(SD)8例,疾病进展(PD)4例,死亡3例。1年存活率100%,2年存活率96%。结论:甲磺酸伊马替尼治疗晚期胃肠间质瘤有较好疗效,能延长患者生命,不良反应轻微,患者能长期耐受。
|
关 键 词: | 胃肠间质瘤 甲磺酸伊马替尼 晚期 |
Clinical Efficacy on Imatinib Mesylate Treatment for Patients with Advanced Gastrointestinal Stromal Tumors |
| |
Affiliation: | CHEN Jie,ZHONG Keli,GUO Chunhua,et al(Shenzhen People’s Hospital,Guangdong Shenzhen 518020,China) |
| |
Abstract: | Objective: To evaluate the efficacy and toxicity of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors.Method:A total of 25 cases with advanced gastrointestinal stromal tumors that all proven by pathology were received imatinib mesylate at doses of 400mg/d,from Oct.2006 to Oct.2010.Result: All cases were followed up.None had complete response,13 cases achieved partial response(PR),8 cases achieved stable disease(SD) and 4 had progression disease(PD).The overall survival rates at 1 and 2 year was 100% and 96% respectively.25 patients were valuable for the toxicity assessment according to the WHO standard.Conclusion: Imatinib mesylate is a safe and efficacious drug used for the patients with advanced gastrointestinal stromal tumors.Only mild adverse reactions occur and toxicity is acceptable. |
| |
Keywords: | Gastrointestinal stromal tumors Imatinib mesylate Advanced |
本文献已被 CNKI 维普 万方数据 等数据库收录! |
|